GreenLight Biosciences Holdings, PBC

2023 Q2 Form 10-Q Financial Statement

#000095017023020835 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $32.35M $83.22M
YoY Change -61.13% 42044.63%
Cash & Equivalents $32.40M $83.20M
Short-Term Investments
Other Short-Term Assets $5.347M $8.725M
YoY Change -38.72% 843.65%
Inventory
Prepaid Expenses $8.725M
Receivables $5.000M
Other Receivables $0.00
Total Short-Term Assets $37.70M $96.95M
YoY Change -61.12% 8540.18%
LONG-TERM ASSETS
Property, Plant & Equipment $40.44M $22.88M
YoY Change 76.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.400M $1.285M
YoY Change 8.95%
Total Long-Term Assets $75.99M $25.48M
YoY Change 198.22% -87.69%
TOTAL ASSETS
Total Short-Term Assets $37.70M $96.95M
Total Long-Term Assets $75.99M $25.48M
Total Assets $113.7M $122.4M
YoY Change -7.14% -41.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.073M $6.049M
YoY Change -82.26%
Accrued Expenses $11.48M $9.398M
YoY Change 22.13% 832.85%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $13.78M $9.849M
YoY Change 39.93%
Total Short-Term Liabilities $31.19M $29.52M
YoY Change 5.63% 2830.57%
LONG-TERM LIABILITIES
Long-Term Debt $10.86M $23.69M
YoY Change -54.16%
Other Long-Term Liabilities $991.0K $1.809M
YoY Change -45.22% -84.51%
Total Long-Term Liabilities $991.0K $1.809M
YoY Change -45.22% -84.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.19M $29.52M
Total Long-Term Liabilities $991.0K $1.809M
Total Liabilities $91.75M $58.60M
YoY Change 56.56% 361.98%
SHAREHOLDERS EQUITY
Retained Earnings -$449.1M -$291.8M
YoY Change 53.91%
Common Stock $15.00K $13.00K
YoY Change 15.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.94M $63.83M
YoY Change
Total Liabilities & Shareholders Equity $113.7M $122.4M
YoY Change -7.14% -41.17%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLongTermDebtNoncurrent
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLongTermDebtNoncurrent
CY2022Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLongTermDebtNoncurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001822691
CY2023Q1 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLongTermDebt
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLongTermDebtNoncurrent
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNet
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNet
CY2022Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OperatingLeaseRightOfUseAsset
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent
CY2022Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OperatingLeaseRightOfUseAsset
CY2023Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39894
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
GreenLight Biosciences Holdings, PBC
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1914700
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
29 Hartwell Avenue
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Lexington
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02421
CY2023Q1 dei City Area Code
CityAreaCode
617
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
616-8188
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
GRNA
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
151681314
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32350000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68097000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5347000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3214000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
37697000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
71311000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1411000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1321000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
40441000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41365000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32740000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32766000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1400000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1835000
CY2023Q1 us-gaap Assets
Assets
113689000
CY2022Q4 us-gaap Assets
Assets
148598000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1073000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
839000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11478000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13544000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4083000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3358000
CY2023Q1 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
13782000
CY2022Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
13229000
CY2023Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
47000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3866000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
724000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
724000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
31187000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
35560000
CY2023Q1 grna Warrant Liabilities
WarrantLiabilities
15000
CY2022Q4 grna Warrant Liabilities
WarrantLiabilities
242000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
48702000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
49569000
CY2023Q1 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
10858000
CY2022Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
14326000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
991000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
839000
CY2023Q1 us-gaap Liabilities
Liabilities
91753000
CY2022Q4 us-gaap Liabilities
Liabilities
100536000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
151681314
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
151681314
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
151587165
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
151587165
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
15000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
15000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
471028000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
468685000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-449107000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-420638000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
21936000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
48062000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
113689000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
148598000
CY2023Q1 grna License And Collaboration Revenue
LicenseAndCollaborationRevenue
3820000
CY2022Q1 grna License And Collaboration Revenue
LicenseAndCollaborationRevenue
0
CY2023Q1 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
0
CY2022Q1 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
257000
CY2023Q1 us-gaap Revenues
Revenues
3820000
CY2022Q1 us-gaap Revenues
Revenues
257000
CY2023Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
23168000
CY2022Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
27281000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8944000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9755000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
32112000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
37036000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-28292000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-36779000
CY2023Q1 grna Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
603000
CY2022Q1 grna Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
4000
CY2023Q1 us-gaap Interest Expense
InterestExpense
1007000
CY2022Q1 us-gaap Interest Expense
InterestExpense
1073000
CY2023Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
227000
CY2022Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-359000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-177000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1428000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-28469000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-38207000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
151614008
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
151614008
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113558404
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113558404
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
48062000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
35000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2308000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-28469000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
21936000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-29975000
CY2022Q1 grna Adjustments To Additional Paid In Capital Exercise Of Convertible Preferred Stock Warrant
AdjustmentsToAdditionalPaidInCapitalExerciseOfConvertiblePreferredStockWarrant
460000
CY2022Q1 grna Stock Issued During Period Value Exercise Of Common Stock Warrants
StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants
1183000
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
18291000
CY2022Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
26700000
CY2022Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
72989000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
22000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2187000
CY2022Q1 grna Stock Issued During Period Value Exercise Of Public Warrants
StockIssuedDuringPeriodValueExerciseOfPublicWarrants
1209000
CY2022Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
65000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-38207000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
63826000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-28469000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-38207000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2334000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2096000
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
9000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2308000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2187000
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
109000
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
335000
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-227000
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
359000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1031000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1631000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1842000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6259000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5000000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
233000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1952000
CY2023Q1 grna Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
-2718000
CY2022Q1 grna Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
-9435000
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3819000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
4743000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31060000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-49511000
CY2022Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
37000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1608000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
287000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1608000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-250000
CY2022Q1 grna Proceeds From Business Combination Net Of Transaction Costs
ProceedsFromBusinessCombinationNetOfTransactionCosts
80491000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
35000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
22000
CY2023Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
2941000
CY2022Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
815000
CY2022Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1209000
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
83000
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
160000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2989000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
102497000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-35657000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
52736000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69418000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31808000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33761000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84544000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
744000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
620000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
396000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1313000
CY2022Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
53541000
CY2022Q1 grna Cashless Warrant Exercises
CashlessWarrantExercises
1643000
CY2022Q1 grna Noncash Or Part Noncash Acquisition Liabilities Assumed Warrants
NoncashOrPartNoncashAcquisitionLiabilitiesAssumedWarrants
1341000
CY2022Q1 grna Deferred Financing Costs In Accrued Expenses And Accounts Payable
DeferredFinancingCostsInAccruedExpensesAndAccountsPayable
1948000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32350000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83223000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1411000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1321000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33761000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84544000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-28500000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-38200000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-449100000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32400000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31100000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-49500000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32400000
CY2022Q1 grna Authorized Shares Capital
AuthorizedSharesCapital
510000000
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 grna Business Combination Gross Proceeds
BusinessCombinationGrossProceeds
136373000
CY2022Q1 grna Business Combination Transaction Costs Paid
BusinessCombinationTransactionCostsPaid
26660000
CY2022Q1 grna Business Combination Transaction Costs And Paid In Two Thousand Twenty One
BusinessCombinationTransactionCostsAndPaidInTwoThousandTwentyOne
4080000
CY2022Q1 grna Cash Proceeds From Business Combination
CashProceedsFromBusinessCombination
78543000
CY2022Q1 grna Noncash Or Part Noncash Acquisition Transaction Costs Paid
NoncashOrPartNoncashAcquisitionTransactionCostsPaid
4080000
CY2022Q1 grna Noncash Or Part Noncash Acquisition Liabilities Assumed Warrants
NoncashOrPartNoncashAcquisitionLiabilitiesAssumedWarrants
1341000
CY2022Q1 us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
133000
CY2022Q1 grna Reverse Merger Net Of Transactions Costs
ReverseMergerNetOfTransactionsCosts
72989000
CY2022Q1 grna Common Stock Shares Outstanding Prior To Business Combination
CommonStockSharesOutstandingPriorToBusinessCombination
20700000
CY2022Q1 grna Redemption Of Common Shares
RedemptionOfCommonShares
19489626
CY2022Q1 grna Shares Issued In Private Investment In Public Equity Financing
SharesIssuedInPrivateInvestmentInPublicEquityFinancing
12425000
CY2022Q1 grna Shares Issued In Business Combination And Private Investment In Public Equity Financing
SharesIssuedInBusinessCombinationAndPrivateInvestmentInPublicEquityFinancing
18810374
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
122822134
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
5000000.0
CY2023Q1 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
4800000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
151681314
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
151681314
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
151587165
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
151587165
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12383304
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12383304
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
469000
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
519000
CY2023Q1 grna Lease Assets
LeaseAssets
33209000
CY2022Q4 grna Lease Assets
LeaseAssets
33285000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4083000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3358000
CY2023Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
134000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2308000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2187000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number
SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
292650
CY2023Q1 grna Share Based Compensation Arrangement By Share Based Payment Award Modified Vesting Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedVestingDate
2022-03-31
CY2023Q1 grna Share Based Payment Award Fair Value Assumptions Grant Date Modification Fair Value
ShareBasedPaymentAwardFairValueAssumptionsGrantDateModificationFairValue
2100000
CY2023Q1 grna Incremental Stock Based Compensation Recognizable On Event Of Business Combination
IncrementalStockBasedCompensationRecognizableOnEventOfBusinessCombination
1400000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-28469000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-38207000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
151614008
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
151614008
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113558404
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113558404
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34814429
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
30891334
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15200000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
15900000
CY2021Q4 grna Unamortized Lease Incentives
UnamortizedLeaseIncentives
700000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32740000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32766000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
210000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
48702000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
49569000
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
22000
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
28000
CY2023Q1 grna Lease Liabilities
LeaseLiabilities
52941000
CY2022Q4 grna Lease Liabilities
LeaseLiabilities
53165000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
2498000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
2519000
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
8000
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
140000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
764000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
86000
CY2023Q1 grna Operating Lease Cost Net
OperatingLeaseCostNet
3270000
CY2022Q1 grna Operating Lease Cost Net
OperatingLeaseCostNet
2745000
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
50000
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
47000
CY2023Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
3000
CY2022Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
6000
CY2023Q1 grna Finance Lease Cost Net
FinanceLeaseCostNet
53000
CY2022Q1 grna Finance Lease Cost Net
FinanceLeaseCostNet
53000
CY2023Q1 us-gaap Lease Cost
LeaseCost
3323000
CY2022Q1 us-gaap Lease Cost
LeaseCost
2798000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2470000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2040000
CY2023Q1 grna Finance Lease Payments
FinanceLeasePayments
3000
CY2022Q1 grna Finance Lease Payments
FinanceLeasePayments
6000
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
83000
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
160000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
791000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
18100000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y3M29D
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y29D
CY2023Q1 grna Operating Lease Weighted Average Incremental Borrowing Rate
OperatingLeaseWeightedAverageIncrementalBorrowingRate
0.1116
CY2022Q1 grna Operating Lease Weighted Average Incremental Borrowing Rate
OperatingLeaseWeightedAverageIncrementalBorrowingRate
0.1109
CY2023Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M
CY2022Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M29D
CY2023Q1 grna Finance Lease Weighted Average Incremental Borrowing Rate
FinanceLeaseWeightedAverageIncrementalBorrowingRate
0.0767
CY2022Q1 grna Finance Lease Weighted Average Incremental Borrowing Rate
FinanceLeaseWeightedAverageIncrementalBorrowingRate
0.0575
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
6828000
CY2023Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
130000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
9568000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
32000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
8280000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
0
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8204000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
0
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
8185000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0
CY2023Q1 grna Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
46183000
CY2023Q1 grna Finance Lease Liability To Be Paid After Year Four
FinanceLeaseLiabilityToBePaidAfterYearFour
0
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
87248000
CY2023Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
162000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
34463000
CY2023Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
6000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
52785000
CY2023Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
156000

Files In Submission

Name View Source Status
grna-20230331_def.xml Edgar Link unprocessable
grna-20230331_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0000950170-23-020835-index-headers.html Edgar Link pending
0000950170-23-020835-index.html Edgar Link pending
0000950170-23-020835.txt Edgar Link pending
0000950170-23-020835-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
grna-20230331.htm Edgar Link pending
grna-20230331.xsd Edgar Link pending
grna-ex31_1.htm Edgar Link pending
grna-ex31_2.htm Edgar Link pending
grna-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
grna-20230331_lab.xml Edgar Link unprocessable
grna-20230331_pre.xml Edgar Link unprocessable
grna-20230331_htm.xml Edgar Link completed
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending